Pharmacovigilance has always been one of the most operationally complex—and failure-prone—areas of the regulatory lifecycle. It depends on the timely intake of adverse event data, accurate case assessment and classification, strict reporting timelines, and continuous signal detection across large and often fragmented datasets. When these systems break down, the consequences are immediate: delayed reporting, missed signals, and regulatory findings that can escalate quickly.
Regulatory inspections consistently show that these failures are rarely isolated. Instead, they stem from systemic weaknesses across intake, evaluation, reporting timelines, and oversight structures.
Against this backdrop, AI is now being introduced directly into these same workflows. That raises a more fundamental question than simply whether AI is useful:
Is AI improving pharmacovigilance systems—or amplifying the risks that already exist within them?
One of the clearest signals that this is no longer theoretical comes from recent FDA enforcement activity.
In a warning letter, the FDA explicitly cited a company for relying on AI-generated outputs to support regulated processes without adequate validation or oversight. The company had used AI tools to generate procedures and specifications, but failed to ensure that those outputs were accurate, complete, or aligned with regulatory requirements. The FDA’s response was unambiguous: AI-generated content must be reviewed and approved by qualified personnel, and failure to do so represents a compliance violation.
While the warning letter was not specific to pharmacovigilance, it is a strong analog for how FDA is likely to view AI use in other regulated quality and safety workflows: the tool does not shift accountability, and AI-generated outputs still require validation, review, and oversight. If AI is used to triage cases, classify adverse events, or generate safety narratives without proper validation and oversight, the same regulatory expectations apply.
This is the key shift:
AI is no longer outside the regulatory framework—it is being evaluated within it.
AI is already being used across core pharmacovigilance activities, including automated case intake, data extraction from safety reports, adverse event classification, narrative generation, and signal detection across large datasets. These are not peripheral use cases—they sit directly inside regulated workflows that determine how safety data is interpreted and reported.
Once AI influences case validity, event classification, signal prioritization, or reporting content, it becomes part of the sponsor’s regulated PV process and should be governed accordingly. This distinction matters because it brings AI under the same expectations that apply to any other regulated component: it must be validated, documented, monitored, and subject to oversight.
Although there is limited pharmacovigilance-specific AI guidance, regulators are not starting from scratch. Instead, they are applying existing regulatory principles—particularly from FDA and EMA frameworks—directly to AI-enabled workflows.
At the core of these expectations is a risk-based approach. AI systems are evaluated based on their impact on patient safety and regulatory decision-making. High-impact use cases, such as signal detection or case classification, require rigorous validation and documentation. Lower-impact use cases may require less oversight but still need verification to ensure outputs are accurate and appropriate.
FDA’s current draft framework for AI supporting regulatory decision-making in drugs and biologics reinforces a risk-based approach built around context of use, model risk, and credibility assessment. While not specific to pharmacovigilance, the same logic is highly relevant to PV workflows.
Alongside risk, regulators are placing increasing emphasis on validation. AI outputs are not assumed to be reliable. Whether generating case narratives or supporting signal detection, outputs must be verified against source data and be defensible under inspection. The expectation is clear: AI does not replace validation, it requires more of it.
Data quality is another critical area. AI systems depend entirely on the integrity and completeness of underlying data. In pharmacovigilance, where data often comes from multiple sources and formats, weak data governance can lead directly to misclassification, missed signals, or delayed reporting. These are not technical issues; they are regulatory failures.
Human oversight remains central. Regulators expect that AI-generated outputs are reviewed by qualified personnel, with clear accountability for decisions. However, as AI scales, this introduces new risks around over-reliance and reduced scrutiny—issues that regulators are increasingly aware of.
Finally, AI is treated as a dynamic system. Regulators expect continuous monitoring, periodic revalidation, and controlled change management. Without this, models that were initially compliant can drift over time and introduce new risks.
The regulatory implications of AI become more tangible when mapped to specific pharmacovigilance functions.
| PV Function | How AI is Used | Regulatory Risk |
| Case Intake & Triage | Automated case detection and prioritization | Valid cases missed or incorrectly rejected |
| Case Processing | Data extraction and classification | Misclassification of seriousness or causality |
| Narrative Generation | AI-generated safety summaries | Inaccurate or incomplete reporting |
| Signal Detection | Pattern recognition across datasets | Failure to detect emerging safety signals |
| Literature Monitoring | Automated scanning and extraction | Missed relevant publications or misinterpretation |
| Aggregate Reporting | Data summarization for submissions | Inconsistent or non-defensible outputs |
What becomes clear is that AI is not operating at the edges—it is embedded directly within decision points that determine compliance outcomes.
Pharmacovigilance systems already have well-documented failure points. These include inconsistent case intake, poor data quality, weak vendor oversight, and gaps in quality systems. AI does not eliminate these issues. In many cases, it accelerates them.
A weak intake process, when automated, can lead to faster rejection of valid cases. Poor data quality can result in more efficient—but still incorrect—classification. Inconsistent oversight can allow AI-generated outputs to pass through unchecked. And insufficient vendor governance can obscure errors until they surface during inspection.
This is the central risk:
AI does not introduce entirely new problems—it scales the ones that already exist.
Many of the challenges seen in early AI adoption follow familiar patterns. Organizations often treat AI as an operational tool, if efficiency gains do not carry regulatory implications. In pharmacovigilance, this assumption rarely holds, as even seemingly minor automation can influence regulated outcomes.
There is also a tendency to rely heavily on vendors, with the assumption that validation and compliance have been addressed externally. Vendor qualification does not replace sponsor accountability; AI functionality, data handling, performance limits, change management, and human review responsibilities still need to be defined in the sponsor’s own quality system. In reality, regulatory accountability remains with the sponsor, regardless of where the tool originates.
Documentation is another common gap. AI systems are frequently implemented without being properly reflected in SOPs, validation records, or quality systems. This creates immediate exposure during inspections.
Finally, lifecycle management is often overlooked. AI models are deployed but not continuously monitored or revalidated, introducing long-term compliance risks as models drift or degrade.
AI is not being restricted in pharmacovigilance, but it is being pulled firmly into the regulatory framework. This means that expectations around validation, documentation, and oversight are increasing—not decreasing.
At the same time, the benefits of AI remain significant. When implemented correctly, AI can improve efficiency in case processing, enhance signal detection, and reduce operational burden. However, these benefits are only realized when AI is deployed within a controlled and well-governed system.
Organizations that approach AI as a regulated component of pharmacovigilance—not just an efficiency tool—will be better positioned to manage both risk and opportunity.
AI is being introduced into one of the most sensitive areas of the regulatory lifecycle—one where failures are already well understood and closely monitored by regulators.
The emerging regulatory position is clear. AI is not exempt from existing expectations. If it influences safety data, it must be validated, documented, continuously monitored, and subject to human oversight.
The recent FDA warning letter reinforces this point: the use of AI does not reduce regulatory responsibility. If anything, it increases the expectation for control and verification.
For organizations, the challenge is not whether to adopt AI, but how to integrate it in a way that maintains compliance, transparency, and accountability.
At dicentra, we support organizations in integrating AI into pharmacovigilance and safety monitoring in a way that aligns with regulatory expectations.
We help teams assess where AI is impacting PV workflows, identify compliance risks, validate AI systems and outputs, and align processes with FDA and EMA expectations. We also support the implementation of governance frameworks that ensure ongoing monitoring and inspection readiness.
AI can significantly improve pharmacovigilance operations, but only when it is implemented with the same rigor as the systems it is intended to support.
Contact dicentra today for guidance on inspection-ready pharmacovigilance support.